Search Results

DermBiont announced updates on the company’s development pipeline, including the completion of enrollment in a Phase 2b clinical trial of SM-020 gel 1.0% for the treatment of SKs, and anticipated clinical milestones for 2024.

DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, today announced a $35.2 million Series B financing, including a $27.1 million Series B first close and $8.1 million in converting outstanding notes.

DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, today announced positive data from its Phase 2 trial with 0.8% SM-030 gel, a product under development capable of regulating pigmentation by controlling the formation of new melanin.

DermBiont today announced that its Phase 2 adaptive design trial with of investigational drug SM-020 gel 1.0% met its primary endpoint of a one point improvement in Physician’s lesion assessment (PLA) score at last visit and safety via local tolerability, as well as key multiple secondary endpoints including complete clearance of treated lesions.

DermBiont announced today that it has raised a $28 million Series A2 financing in parallel with the acquisition of clinical-stage biotechnology company Chromaderm.

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

DermBiont, a clinical-stage biotechnology company announced today positive results meeting primary and secondary endpoints in a Phase 2 clinical trial with a topical formulation of investigational drug SM-020, a specific and potent AKT inhibitor applied by patients at home to their seborrheic keratoses (SK).

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system